JP2018513869A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513869A5
JP2018513869A5 JP2017555387A JP2017555387A JP2018513869A5 JP 2018513869 A5 JP2018513869 A5 JP 2018513869A5 JP 2017555387 A JP2017555387 A JP 2017555387A JP 2017555387 A JP2017555387 A JP 2017555387A JP 2018513869 A5 JP2018513869 A5 JP 2018513869A5
Authority
JP
Japan
Prior art keywords
dosage form
unit dosage
pharmaceutical unit
apomorphine
film
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017555387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513869A (ja
JP7211706B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/028265 external-priority patent/WO2016172095A1/en
Publication of JP2018513869A publication Critical patent/JP2018513869A/ja
Publication of JP2018513869A5 publication Critical patent/JP2018513869A5/ja
Priority to JP2021042988A priority Critical patent/JP2021105006A/ja
Application granted granted Critical
Publication of JP7211706B2 publication Critical patent/JP7211706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017555387A 2015-04-21 2016-04-19 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法 Active JP7211706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021042988A JP2021105006A (ja) 2015-04-21 2021-03-17 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562150624P 2015-04-21 2015-04-21
US62/150,624 2015-04-21
PCT/US2016/028265 WO2016172095A1 (en) 2015-04-21 2016-04-19 Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021042988A Division JP2021105006A (ja) 2015-04-21 2021-03-17 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Publications (3)

Publication Number Publication Date
JP2018513869A JP2018513869A (ja) 2018-05-31
JP2018513869A5 true JP2018513869A5 (enExample) 2019-05-30
JP7211706B2 JP7211706B2 (ja) 2023-01-24

Family

ID=57143420

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017555387A Active JP7211706B2 (ja) 2015-04-21 2016-04-19 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法
JP2021042988A Ceased JP2021105006A (ja) 2015-04-21 2021-03-17 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021042988A Ceased JP2021105006A (ja) 2015-04-21 2021-03-17 口腔粘膜へのアポモルフィンの投与によるパーキンソン病の治療方法

Country Status (7)

Country Link
US (3) US10449146B2 (enExample)
EP (2) EP3285771B1 (enExample)
JP (2) JP7211706B2 (enExample)
CA (2) CA3127926A1 (enExample)
ES (1) ES3015535T3 (enExample)
PT (1) PT3285771T (enExample)
WO (1) WO2016172095A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651357B1 (en) 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2021515034A (ja) * 2018-02-22 2021-06-17 アビオール、インコーポレイテッド 経粘膜フィルム組成物ならびにそれを作製及び使用する方法
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
WO2020041683A2 (en) 2018-08-23 2020-02-27 Sunovion Pharmaceuticals Inc. Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
EP3917502A4 (en) * 2019-01-28 2022-10-12 Sunovion Pharmaceuticals Inc. METHOD OF TREATMENT OF A PATIENT WITH PARKINSON'S DISEASE
EP3989909A1 (en) 2019-06-27 2022-05-04 Sunovion Pharmaceuticals Inc. Child-resistant dispensers for thin strip medications

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1482151A (en) 1973-07-19 1977-08-10 Kennecott Copper Corp Processes for selectively recovering nickel valves
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4614545A (en) 1985-08-15 1986-09-30 The Dow Chemical Company Hydroxypropyl methyl cellulose thickening agents for organic liquids
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
DE4018247A1 (de) 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE184473T1 (de) 1992-06-11 1999-10-15 Theratech Inc Verwendung von glyzerin zur dämpfung der transdermalen arzneimittelverabreichung
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5700478A (en) 1993-08-19 1997-12-23 Cygnus, Inc. Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US6566368B2 (en) 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
ATE312609T1 (de) 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5523090A (en) 1995-02-24 1996-06-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin treatment composition
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US20010006677A1 (en) 1996-10-29 2001-07-05 Mcginity James W. Effervescence polymeric film drug delivery system
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
US6667056B2 (en) 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
GB9826192D0 (en) 1998-12-01 1999-01-20 Controlled Theraputics Scotlan Oral transmucosal delivery
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
DE19954245A1 (de) 1999-11-11 2001-07-19 Lohmann Therapie Syst Lts Mehrschichtige filmförmige Zubereitung aus hydrophilen Polymeren zur schnellen Freisetzung von Wirkstoffen
DE19954421A1 (de) 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
IL155667A0 (en) * 2000-11-15 2003-11-23 Tap Pharmaceutical Prod Inc Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US6756051B1 (en) 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
CA2435546A1 (en) 2001-02-08 2002-08-15 Alice C. Martino Rapid-onset medicament for the treatment of sexual dysfunction
US20040063742A1 (en) * 2001-02-15 2004-04-01 Dan Peters Treatment of parkinson's disease by the combined action of a compound with neurotrophic activity and a compound enhancing the dopamine activity
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20080050422A1 (en) 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
JP2004043450A (ja) 2002-05-16 2004-02-12 Kyukyu Yakuhin Kogyo Kk 速溶性フィルム状製剤
DE10224612A1 (de) 2002-06-04 2003-12-24 Lohmann Therapie Syst Lts Wirkstoffhaltige filmförmige Zubereitungen mit verbesserter chemischer Stabilität, und Verfahren zu deren Herstellung
GB0221711D0 (en) 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
AU2003295577A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Edible film for relief of cough or symptoms associated with pharyngitis
US9561182B2 (en) 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP5165888B2 (ja) 2003-01-30 2013-03-21 モノソル・アールエックス・エルエルシー 非自己凝集性で均一な混成を示す薄いフィルム、およびそれから作製した薬物送達システム
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0410956A (pt) 2003-05-28 2006-07-04 Monosolrx Llc pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
JP2005021124A (ja) * 2003-07-02 2005-01-27 Kyukyu Yakuhin Kogyo Kk 口腔用フィルム製剤
PT2446881E (pt) 2003-07-24 2014-06-11 Glaxosmithkline Llc Películas de dissolução oral
CA2543350C (en) 2003-10-24 2011-04-26 Adhesives Research, Inc. Disintegratable films for diagnostic devices
US9248146B2 (en) 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
NZ548215A (en) 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
KR20070007299A (ko) 2004-01-30 2007-01-15 코리움 인터네셔널, 인크. 활성제의 전달을 위한 급속 용해 필름
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
JP4413665B2 (ja) 2004-03-19 2010-02-10 救急薬品工業株式会社 口腔内粘膜フィルム剤
DK1799453T3 (da) 2004-09-30 2012-12-17 Monosolrx Llc Flerlagsfilm med ensartet indhold
RU2283650C1 (ru) 2005-02-24 2006-09-20 Закрытое Акционерное Общество "Канонфарма Продакшн" Твердая лекарственная форма для улучшения мужской эректильной функции
GB0509317D0 (en) 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102005041860A1 (de) 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP1931305A2 (en) 2005-09-09 2008-06-18 MonoSolRX, LLC Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
AU2006322050A1 (en) 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
AU2006329819A1 (en) 2005-12-27 2007-07-05 Monosol Rx Llc pH modulated films for delivery of actives
ES2577390T3 (es) 2006-07-21 2016-07-14 Biodelivery Sciences International, Inc. Dispositivos de administración transmucosa con mayor captación
HUE038022T4 (hu) 2006-10-02 2023-02-28 Spepharm Ag Nem mukoadhezív filmdózisformák
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
MX2010004265A (es) 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
PT2952191T (pt) 2009-06-12 2018-11-30 Sunovion Pharmaceuticals Inc Apomorfina sublingual
WO2012053006A2 (en) * 2010-10-18 2012-04-26 Panacea Biotec Ltd Improved oral fast dissolving films comprising combination of polymers and method of preparation thereof
EP2651357B1 (en) * 2010-12-16 2020-04-01 Sunovion Pharmaceuticals Inc. Sublingual films
GB201217419D0 (en) 2012-09-28 2012-11-14 Innotesto Bvba Improvements in or relating to oromucosal apomorphine compositions
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EP3917502A4 (en) * 2019-01-28 2022-10-12 Sunovion Pharmaceuticals Inc. METHOD OF TREATMENT OF A PATIENT WITH PARKINSON'S DISEASE

Similar Documents

Publication Publication Date Title
JP5786195B2 (ja) 舌下フィルム
CN103889508B (zh) 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置
US9216175B2 (en) Sublingual buprenorphine spray
CA3019769A1 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
EP2081547B1 (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
JP2017206517A (ja) 薬物置換療法のためのブプレノルフィンウェハー
US12201622B2 (en) Continuous delivery of lenalidomide and other immunomodulatory agents
JP2013501718A5 (enExample)
CN1882340A (zh) 用于治疗或预防淀粉样变性病的方法和组合物
KR20180105184A (ko) 록사핀 필름 경구 투여 제형
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
EP2623096A2 (fr) Composition pharmaceutique a liberation prolongée de trimetazidine
WO2005070398A2 (en) Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
US9839611B2 (en) Sublingual buprenorphine spray
JP2007529545A (ja) ダウン症候群の治療法
WO2004052347A1 (de) Transmucosale und transdermale arzneimittel mit verbesserter wirkstoffresorption
EP3870176B1 (en) Use of ambrisentan for the treatment of portal hypertension
WO2024184792A1 (en) Transdermal drug delivery systems for administration of a therapeutically effective amount of apixaban and other direct oral anticoagulants
HK40044248A (en) Treatment method with iap inhibitor
CN112891510A (zh) 采用iap抑制剂的治疗方法
Parikh et al. A single-dose crossover study of fentanyl sublingual spray, oral transmucosal fentanyl citrate, and fentanyl citrate injection (IV) in healthy volunteers
Koland Evaluation of In Vitro Release and In Vivo Transbuccal Permeation of Losartan Potassium from Mucoadhesive Films
Darwish et al. Dose proportionality of a new extended-release hydrocodone formulation in healthy volunteers
Parikh et al. Pharmacokinetic parameters of fentanyl sublingual spray: a single-dose, 5-way crossover study
Singh et al. Controlled 24 hour oral delivery of buprenorphine using a push pull osmotic pump